This article has Open Peer Review reports available.
Visceral symptoms as a key diagnostic sign for the early infantile form of Niemann–Pick disease type C in a Russian patient: a case report
© Degtyareva et al. 2016
Received: 19 September 2015
Accepted: 4 May 2016
Published: 1 June 2016
Niemann–Pick disease type C is a rare metabolic disease characterized by progressive neurological deterioration with childhood onset, and often results in premature mortality. Niemann–Pick disease type C has an extremely heterogeneous clinical presentation with a wide range of visceral and neurological signs and symptoms that are not specific to the disease, and which progress over varied periods of time. The incidence and epidemiology of Niemann–Pick disease type C in Russia have not been characterized. We report the case of a Russian newborn with early-infantile onset Niemann–Pick disease type C who displayed prolonged neonatal jaundice and hepatosplenomegaly.
A 5-year-old white boy born to non-consanguineous Russian parents was originally diagnosed with galactosemia at the age of 2 months based on a raised blood galactose level. A galactose-free and lactose-free diet resulted in achievement of a normal galactose level, but hepatosplenomegaly and cholestatic signs persisted. Liver biopsy results hinted at possible Niemann–Pick disease type C, but differential diagnostic investigations for progressive familial intrahepatic cholestasis type 2 (Byler syndrome) indicated a heterozygous genotype suggestive of this disease. Further, progressive neurological symptoms prompted additional genetic analyses for possible Niemann–Pick disease type C, from which an as-yet unreported combination of known NPC1 gene mutations was identified, and a final diagnosis of Niemann–Pick disease type C was established. The patient subsequently developed typical neurological symptoms of early-infantile Niemann–Pick disease type C, including vertical supranuclear ophthalmoparesis and cerebellar ataxia. Miglustat therapy was initiated 2.5 years ago, and some improvements in movement and speech have since been observed.
This case illustrates the continued challenges associated with diagnosing Niemann–Pick disease type C based on the appearance of nonspecific cholestatic symptoms. Based on this case we recommend examination of all newborns and children who display unexplained cholestasis or isolated splenomegaly/hepatosplenomegaly during the first months of life for other signs of possible Niemann–Pick disease type C.
NP-C has an extremely heterogeneous clinical presentation characterized by a wide range of symptoms that are not specific to the disease, and which arise and progress over varied periods of time [1, 3]. Disease onset occurs in the neonatal period in a notable proportion of patients. In particular, NP-C represents one of the leading metabolic causes of cholestatic syndrome in babies . Non-immune hydrops, ascites, and fetal hepatosplenomegaly are also often described in affected children . Cholestasis and severe splenomegaly in the absence of portal hypertension are considered to be pathognomonic .
We report the case of a 5-year-old boy with early infantile onset NP-C that illustrates some of the challenges associated with diagnosing the disease early on in life based on the appearance of nonspecific cholestatic symptoms.
The patient was a 5-year-old Caucasian boy (weight at birth 2900 g, height at birth 50 cm) born to non-consanguineous parents with no previous medical history of NP-C in Krasnodar, Russia. Jaundice was observed at the age of 3 days and was considered physiological. The child was therefore discharged. However, he was later hospitalized at a child care facility due to continued jaundice and mild hepatosplenomegaly (liver 2.5 cm and spleen 1 cm), at which point raised total and conjugated bilirubin, alkaline phosphatase, cholesterol, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were observed.
The results of his hematology and urine analysis tests were normal, but heightened nervous reflex irritability was observed. Blood polymerase chain reaction (PCR) testing for cytomegalovirus (CMV), herpes simplex virus (HSV), toxoplasmosis, and chlamydia infection were negative. However, a blood galactose of 12 ng/ml (upper limit of normal, 7.1 ng/ml) was observed, which increased to 20 ng/ml at repeat examination. On this basis, galactosemia was suspected and a galactose-free and lactose-free diet was prescribed. By the age of 2 months the patient’s blood galactose level was normalized, but cholestasis and hepatosplenomegaly persisted. He was therefore referred to the Research Center for Obstetrics, Gynecology and Perinatology at the Federal State Budget Institution in Moscow, Russia for further work up.
Blood biochemical analysis at the age of 2 months and 1 week
Total bilirubin, mkM/l
Conjugated bilirubin, mkM/l
Gamma glutamine transferase, U/l
Alkaline phosphatase, U/l
Alanine aminotransferase, U/l
Aspartate aminotransferase, U/l
Creatine phosphokinase, U/l
Prothrombin time index, %
A liver biopsy revealed swollen Kupffer cells with foamy cytoplasm, which are considered typical histopathological hallmarks of NP-C (Fig. 1). A preliminary diagnosis of NP-C was therefore concluded. No causal NPC2 gene mutations were detected; while parallel investigations for progressive familial intrahepatic cholestasis type 2 (Byler syndrome) indicated a heterozygous genotype suggestive of this disease.
Typical symptoms of Byler syndrome include progressive cholestasis with low blood gamma glutamyltransferase (GGT) levels and severe pruritus. Liver transplantation is always indicated for Byler syndrome because of its association with biliary cirrhosis and poor quality of life. During the examination of our patient at the age of 2 to 3 months he had slightly increased (near-normal) GGT and he was too young for pruritus. Pruritus usually appears at the age of 4 to 5 months or later, which is why we could not exclude Byler syndrome. On the other hand we could not insist on the performance of genetic testing for NPC1 in this case because of the expense involved and the fact that his family was not ready.
The patient undertook a high medium-chain triglyceride diet with fat-soluble vitamins, and ursodeoxycholic acid therapy. Jaundice eventually disappeared by 5 months of age, and by the age of 2 years his hepatomegaly had resolved. His splenomegaly had also decreased (6 to 7 cm). Later on it became obvious that he did not have Byler syndrome as his cholestasis resolved, he did not have pruritus, and he had splenomegaly without portal hypertension. He was therefore not indicated for liver transplantation. On balance, we decided to suspend further genetic testing.
After a bout of acute otitis he stopped walking on his own aged 2 years and 10 months. He also stopped eating independently due to a pronounced tremor. Brain MRI findings were normal. These neurological symptoms prompted further diagnostic tests for possible NP-C, and complete NPC1 gene mutation analysis identified an as yet unreported combination of known mutations c.2777C>T (p.Ala926Val: CM077214) and c.2196_2197insT.
Retrospective analysis of his neurological status showed normal psychomotor development during his first year of life, but he did display minor deficits (for example, inward turning of his feet, awkward gait) that were probably the first neurological disease manifestations. An observable tremor first appeared when he was 2.5-years old.
At the time of reporting he is 5-years old and displays abnormal saccadic eye movements, trunk ataxia, hypotonia, subcortical cerebellar dysarthria and dysmetria, and intention tremor. He continues to walk with assistance but his gait is ataxic-polyneuropathic. He has also lost 2 kg in body weight since the initial onset of neurological manifestations, and displays signs of first-degree hypotrophy. His splenomegaly persists (spleen size, 7 cm).
Miglustat (Zavesca®; Actelion Pharmaceuticals Ltd) was initiated 2.5 years ago with appropriate dietary alterations. Positive changes have since been observed, including reduced tremor and decreased muscle hypotonia. The patient can sometimes walk without assistance and he exhibits a degree of improvement in his speech. He has also gained weight. His liver function test results remain normal, and splenomegaly has persisted without signs of portal hypertension.
This case report is based on a typical case of early-infantile onset NP-C, and illustrates some of the challenges associated with diagnosing patients with NP-C early on in life based on the appearance of nonspecific cholestatic symptoms. Despite the appearance of neonatal cholestasis, which prompted investigations for possible Gaucher disease (GD) or galactosemia, neurological signs suggestive of NP-C only became apparent at the end of the first year of life [1, 3].
Cholestasis and splenomegaly were the first clinical signs of NP-C in our patient, and NP-C ranks highly among possible metabolic causes of neonatal cholestasis . Nevertheless, a differential diagnosis was performed in a way that took into account an extensive group of other metabolic and non-metabolic diseases, including: GD, galactosemia, α-1-antitrypsin deficiency, tyrosinemia, citrullinemia type 2, progressive familial intrahepatic cholestasis type 3, mitochondrial disorders, Alagille syndrome, and others.
Swollen Kupffer cells with foamy cytoplasm in liver biopsy specimens was the first strong sign of NP-C, but even these histopathological changes are not specific to the disease . Filipin staining in cultured skin fibroblasts is considered a key diagnostic test for NP-C [1, 3], but it was not applied in our patient due to technical difficulties. Genetic testing has increasingly been used in the detection of NP-C over the last decade, particularly among patients with nonspecific, albeit suggestive, clinical symptoms. In this case, NPC1 mutation analysis was only applied after the appearance of neurological disorders, and it identified known mutations allowing a full confirmation of the diagnosis.
NP-C pathognomonic symptoms such as vertical supranuclear ophthalmoparesis, and cerebellar signs such as ataxia, dysarthria, and dystonia, only became evident 2 years ago (when our patient was 3-years old). The comprehensive characterization of the time of onset, nature, and severity of neurological signs is considered vital for diagnosing NP-C, but can be very challenging in children below 2 years of age . A recently developed pediatric version of the NP-C suspicion index alongside plasma oxysterol testing might help in this respect, in future cases .
A targeted treatment for neurological deterioration that has been reported to slow disease progression and improve patients’ quality of life is now available for NP-C . In view of this case, we consider it important to examine all newborns and children who display unexplained cholestasis or isolated splenomegaly/hepatosplenomegaly during the first months of life for signs of possible NP-C.
Matthew Reilly PhD at InTouch Medical Ltd provided medical writing support, paid for by Actelion Pharmaceuticals Ltd.
As corresponding author, AVD coordinated the specialist clinical care of the patient, wrote the first draft of the manuscript, and was involved at all writing stages of the manuscript content. SVM, EYuZ, ELT, and AAP all contributed to the clinical assessments and reviewed and provided critical input to the manuscript content. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised in 2000. Written informed consent was obtained from the patient’s parent for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16.View ArticlePubMedPubMed CentralGoogle Scholar
- Mikhailova SV, Zakharova E. Niemann-Pick type C disease. Clinical case studies. Pediatr Pharmacol. 2010;7:48–53.Google Scholar
- Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F, on behalf of the NP-C Guidelines Working Group. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab. 2012;106:330–44.Google Scholar
- Kelly DA, Portmann B, Mowat AP, Sherlock S, Lake BD. Niemann-Pick disease type C: diagnosis and outcome in children, with particular reference to liver disease. J Pediatr. 1993;123:242–7.View ArticlePubMedGoogle Scholar
- Pineda M, Mengel E, Héron B, van der Linden V, Imrie J, Jones SA, Lourenço C, Jahnová H, Jesina P, Karimzadeh P. A Niemann-Pick disease Type C Suspicion Index tool to aid diagnosis in paediatric patients. J Inherit Metab Dis. 2014;37 Suppl 1:S140.Google Scholar